These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

278 related items for PubMed ID: 27637350

  • 1. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide.
    Baciarello G, Sternberg CN.
    Crit Rev Oncol Hematol; 2016 Oct; 106():14-24. PubMed ID: 27637350
    [Abstract] [Full Text] [Related]

  • 2. [Enzalutamide-a novel androgen receptor inhibitor that provides treatment options for patients with castration-resistant prostate cancer].
    Maeda H, Saito A.
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):805-10. PubMed ID: 25131864
    [Abstract] [Full Text] [Related]

  • 3. Enzalutamide for the treatment of nonmetastatic castration-resistant prostate cancer.
    Altavilla A, Casadei C, Lolli C, Menna C, Ravaglia G, Gurioli G, Farolfi A, Brighi N, Conteduca V, Burgio SL, Schepisi G, Rossi L, Gargiulo S, Lisotti I, De Giorgi U.
    Expert Opin Pharmacother; 2020 Dec; 21(17):2091-2099. PubMed ID: 32783772
    [Abstract] [Full Text] [Related]

  • 4. Safety and effectiveness of enzalutamide in men with metastatic, castration-resistant prostate cancer.
    Graff JN, Gordon MJ, Beer TM.
    Expert Opin Pharmacother; 2015 Apr; 16(5):749-54. PubMed ID: 25687355
    [Abstract] [Full Text] [Related]

  • 5. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
    Taplin ME, Antonarakis ES, Ferrante KJ, Horgan K, Blumenstein B, Saad F, Luo J, de Bono JS.
    Eur Urol; 2019 Dec; 76(6):843-851. PubMed ID: 31542304
    [Abstract] [Full Text] [Related]

  • 6. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer.
    Schalken J, Fitzpatrick JM.
    BJU Int; 2016 Feb; 117(2):215-25. PubMed ID: 25818596
    [Abstract] [Full Text] [Related]

  • 7. Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer.
    Efstathiou E, Titus M, Wen S, Hoang A, Karlou M, Ashe R, Tu SM, Aparicio A, Troncoso P, Mohler J, Logothetis CJ.
    Eur Urol; 2015 Jan; 67(1):53-60. PubMed ID: 24882673
    [Abstract] [Full Text] [Related]

  • 8. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer.
    Sanford M.
    Drugs; 2013 Oct; 73(15):1723-32. PubMed ID: 24127223
    [Abstract] [Full Text] [Related]

  • 9. [Enzalutamide-new option in metastatic castration-sensitive prostate cancer? : Preliminary results of a randomized phase III trial (ENZAMET)].
    Boegemann M.
    Urologe A; 2020 Jan; 59(1):78-79. PubMed ID: 31853892
    [No Abstract] [Full Text] [Related]

  • 10. The evolving role of enzalutamide on the treatment of prostate cancer.
    Nadal R, Bellmunt J.
    Future Oncol; 2016 Mar; 12(5):607-16. PubMed ID: 26839021
    [Abstract] [Full Text] [Related]

  • 11. Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated: © NICE (2016) Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated.
    BJU Int; 2017 Aug; 120(2):168-184. PubMed ID: 28719114
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis-targeting Agents in Metastatic Castration-resistant Prostate Cancer.
    To SQ, Kwan EM, Fettke HC, Mant A, Docanto MM, Martelotto L, Bukczynska P, Ng N, Graham LK, Parente P, Pezaro C, Mahon K, Horvath L, Todenhöfer T, Azad AA.
    Eur Urol; 2018 Jun; 73(6):818-821. PubMed ID: 29398263
    [Abstract] [Full Text] [Related]

  • 18. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K, Sønksen J, Fode M, Lindberg H, Kistorp CM, Bisbjerg R, Palapattu G, Østergren PB.
    BMJ Open; 2019 Sep 11; 9(9):e030218. PubMed ID: 31511288
    [Abstract] [Full Text] [Related]

  • 19. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer.
    Bernemann C, Schnoeller TJ, Luedeke M, Steinestel K, Boegemann M, Schrader AJ, Steinestel J.
    Eur Urol; 2017 Jan 11; 71(1):1-3. PubMed ID: 27471164
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.